Table 2.

Examples of clinical trials involving the combination of immunotherapy and anti-angiogenic treatment in ovarian cancer

Identifier	Agent/Drug	Study title	Status
NCT02659384	Bevacizumab Atezolizumab Acetylsalicylic Acid	Anti-programmed cell death-1 ligand 1 (aPDL-1) antibody atezolizumab, bevacizumab and acetylsalicylic acid in recurrent platinum resistant ovarian cancer	Active, not recruiting
NCT03353831	Atezolizumab Bevacizumab Chemotherapy	Atezolizumab with bevacizumab and chemotherapy vs. bevacizumab and chemotherapy in early relapse ovarian cancer	Recruiting
NCT03363867	Atezolizumab Bevacizumab Cobimetinib	BEACON – ABC in recurrent platinum resistant HGSOC	Recruiting
NCT04361370	Olaparib Pembrolizumab Bevacizumab	Olaparib maintenance with pembrolizumab & bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer	Not yet recruiting
NCT03596281	Pembrolizumab Bevacizumab Pegylated Liposomal Doxorubicin	Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with ovarian cancer	Not yet recruiting
NCT02853318	Pembrolizumab Bevacizumab Cyclophosphamide	Pembrolizumab, bevacizumab, and cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer	Active, not recruiting

Data from ClinicalTrials.gov.